GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: December 20, 2004, 15:06:06 ; Search time 75 Seconds
(without alignments)
416.126 Million cell updates/sec

Title: US-10-670-911A-1
Perfect score: 480
Sequence: 1 AGKCDAVFKGFSDCLLKLGD.....RKESKNLNIQGSLFELCGSG 87

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2002273 seqs, 358729299 residues

Total number of hits satisfying chosen parameters: 2002273

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_23Sep04:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	480	100.0	87	8	ADM82927	Adm82927 Soluble c
2	480	100.0	142	2	AAW37859	Aaw37859 Human neu
3	480	100.0	142	2	AAW37858	Aaw37858 Rat neuri
4	480	100.0	142	3	AAB10235	Aab10235 Human fet
5	480	100.0	142	4	AAM39848	Aam39848 Human pol
6	480	100.0	142	7	ADE63108	Ade63108 Rat Prote
7	480	100.0	142	7	ADE63114	Ade63114 Human Pro
8	480	100.0	142	7	ADE63112	Ade63112 Rat Prote
9	480	100.0	142	7	ADE63110	Ade63110 Human Pro
10	480	100.0	142	8	ADN04842	Adn04842 Antipsori
11	480	100.0	154	4	AAM41634	Aam41634 Human pol
12	426.5	88.9	143	2	AAW89078	Aaw89078 Polypepti
13	426.5	88.9	143	4	ABB51249	Abb51249 Human sec
14	426.5	88.9	143	6	ABO45506	Abo45506 Novel hum
15	426.5	88.9	143	7	ABO26986	Abo26986 Protein a
16	359.5	74.9	157	4	ABG27831	Abg27831 Novel hum
17	339	70.6	116	2	AAY59990	Aay59990 Human end
18	327	68.1	90	2	AAW89077	Aaw89077 Polypepti
19	327	68.1	90	4	ABB51248	Abb51248 Human sec
20	327	68.1	90	6	ABO45505	Abo45505 Novel hum
21	327	68.1	90	7	ABO26985	Abo26985 Protein a
22	179.5	37.4	127	2	AAW44088	Aaw44088 Human sec
23	179.5	37.4	127	2	AAW27652	Aaw27652 Secreted
24	179.5	37.4	164	3	AAB01380	Aab01380 Neuron-as
25	179.5	37.4	165	4	AAB50972	Aab50972 Human PRO
26	179.5	37.4	165	4	AAM39830	Aam39830 Human pol
27	179.5	37.4	165	5	AAU83706	Aau83706 Human PRO
28	179.5	37.4	165	5	AAU86146	Aau86146 Human PRO
29	179.5	37.4	165	5	ABB84968	Abb84968 Human PRO
30	179.5	37.4	165	5	ABB95574	Abb95574 Human ang
31	179.5	37.4	165	6	ABU80853	Abu80853 Human PRO
32	179.5	37.4	165	6	ABO33819	Abo33819 Novel hum
33	179.5	37.4	165	6	ABU71438	Abu71438 Human neo
34	179.5	37.4	165	6	ABU82162	Abu82162 Novel hum
35	179.5	37.4	165	6	ABJ72342	Abj72342 Human PRO
36	179.5	37.4	165	6	ABJ72470	Abj72470 Human PRO
37	179.5	37.4	165	6	ABO34365	Abo34365 Human sec
38	179.5	37.4	165	7	ABJ72172	Abj72172 Human mem
39	179.5	37.4	165	7	ADB83720	Adb83720 Novel hum
40	179.5	37.4	165	7	ADB80826	Adb80826 Novel hum
41	179.5	37.4	165	7	ADB73367	Adb73367 Novel hum
42	179.5	37.4	165	7	ADB78449	Adb78449 Novel hum
43	179.5	37.4	165	7	ADB85097	Adb85097 Human PRO
44	179.5	37.4	165	7	ADB78203	Adb78203 Novel hum
45	179.5	37.4	165	7	ADB87269	Adb87269 Human PRO

ALIGNMENTS

RESULT 1
ADM82927
ID ADM82927 standard; protein; 87 AA.
XX
AC ADM82927;
XX
DT 01-JUL-2004 (first entry)
XX
DE Soluble candidate plasticity gene s-CPG15 core domain SEQ ID NO:1.
XX
KW cell death; soluble candidate plasticity gene; s-CPG15; CNS; cardiant;
KW gene therapy; Alzheimer's disease; Parkinson's disease;
KW Huntington's disease; amylotrophic lateral sclerosis;
KW traumatic brain injury; stroke; cardiac condition; cardiac ischaemia;
KW s-CPG15 core domain.
XX
OS Homo sapiens.
XX
PN WO2004031347-A2.
XX
PD 15-APR-2004.
XX
PF 24-SEP-2003; 2003WO-US030152.
XX
PR 24-SEP-2002; 2002US-0413238P.
XX
PA (MASI) MASSACHUSETTS INST TECHNOLOGY.
XX
PI Nedivi E, Putz U;
XX
DR WPI; 2004-330162/30.
XX
PT Treating or preventing a condition of excessive cell death in a subject
PT comprises administering to the subject a soluble CPG15 (s-CPG15) compound
PT having s-CPG15 biological activity.
XX
PS Claim 5; SEQ ID NO 1; 92pp; English.
XX
CC The present invention describes a method for treating or preventing a
CC condition of excessive cell death in a subject, which comprises
CC administering to the subject a soluble candidate plasticity gene CPG15 (s
CC -CPG15) compound having s-CPG15 biological activity in an amount and for
CC a time sufficient to prevent, reduce, or eliminate the symptoms of the
CC condition. Also described: (1) a method of reducing or preventing cell
CC death by administering to a cell s-CPG15 in an amount and for a time to
CC reduce or prevent the cell death; (2) a method of promoting the survival
CC or differentiation of a cell by administering to the cell s-CPG15; (3) a
CC composition of matter comprising a purified polypeptide having s-CPG15

CC biological activity; (4) methods of treating or preventing a condition of
CC undesirable cell survival in a subject; (5) methods of enhancing cell
CC death; (6) a composition of matter comprising a purified antibody or
CC antigen-binding fragment that specifically binds S-CPG15, or siRNA that
CC is complementary to an mRNA sequence encoding s-CPG15; (7) a method of
CC manufacturing s-CPG15 by expressing the s-CPG15 protein in a population
CC of cells and isolating from the supernatant of the cell population the s-
CC CPG15; and (8) a method of identifying a candidate compound that
CC modulates cell death, cell survival, or cellular differentiation
CC pathways. s-CPG15 has CNS and cardiant activities, and can be used in
CC gene therapy. The methods are useful for treating or preventing
CC Alzheimer's disease, Parkinson's disease, Huntington's disease,
CC amylotrophic lateral sclerosis, traumatic injury to the brain, or stroke,
CC or a cardiac condition such as cardiac ischaemia. The present sequence
CC represents a specifically claimed s-CPG15 core domain amino acid sequence
CC from the present invention.
XX
SQ Sequence 87 AA;

```
  Query Match             100.0%;  Score 480;  DB 8;  Length 87;
  Best Local Similarity   100.0%;  Pred. No. 7e-51;
  Matches   87;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 60
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 60

Qy         61 KDMWDKLRKESKNLNIQGSLFELCGSG 87
              |||||||||||||||||||||||||||
Db         61 KDMWDKLRKESKNLNIQGSLFELCGSG 87
```

RESULT 2
AAW37859
ID AAW37859 standard; protein; 142 AA.
XX
AC AAW37859;
XX
DT 10-AUG-1998 (first entry)
XX
DE Human neuritin full length amino acid sequence.
XX
KW Human neuritin; antibody; autonomic nervous system; Parkinson's disease;
KW CNS; peripheral nervous system; Alzheimer's disease; tissue implantation.
XX
OS Homo sapiens.
XX
PN WO9806843-A1.
XX
PD 19-FEB-1998.
XX
PF 07-AUG-1997; 97WO-US013949.
XX
PR 09-AUG-1996; 96US-00694579.
XX
PA (AMGE-) AMGEN INC.
PA (YEDA) YEDA RES & DEV CO LTD.
XX
PI Theill LE, Naeve GS;
XX
DR WPI; 1998-159535/14.
DR N-PSDB; AAV29023.
XX
PT New isolated neuritin gene - is used to develop products for treating
PT e.g. Alzheimer's disease, Parkinson's disease, peripheral neuropathy and
PT damaged or degenerated nervous system tissue.
XX
PS Claim 1; Fig 4; 83pp; English.
XX
CC This is the full length amino acid sequence of the human neuritin. The
CC gene products (e.g. antibody, peptide fragments, etc) can be used to
CC treat patients in whom various cells of the central, autonomic, or
CC peripheral nervous system have been degenerated, as well as treatment of
CC e.g. Alzheimer's disease, Parkinson's disease. They can also be used in
CC conjunction with surgical implantation of tissue in the treatment of
CC diseases in which tissue implantation is indicated. The products can also
CC be used for detection and diagnosis
XX
SQ Sequence 142 AA;

```
  Query Match             100.0%;  Score 480;  DB 2;  Length 142;
  Best Local Similarity   100.0%;  Pred. No. 1.3e-50;
  Matches   87;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 60
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         28 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 87

Qy         61 KDMWDKLRKESKNLNIQGSLFELCGSG 87
              |||||||||||||||||||||||||||
Db         88 KDMWDKLRKESKNLNIQGSLFELCGSG 114
```

RESULT 3
AAW37858
ID AAW37858 standard; protein; 142 AA.
XX
AC AAW37858;
XX
DT 10-AUG-1998 (first entry)
XX
DE Rat neuritin full length amino acid sequence.
XX
KW Rat neuritin; antibody; autonomic nervous system; Parkinson's disease;
KW CNS; peripheral nervous system; Alzheimer's disease; tissue implantation.
XX
OS Rattus sp.
XX
PN WO9806843-A1.
XX
PD 19-FEB-1998.
XX
PF 07-AUG-1997; 97WO-US013949.
XX
PR 09-AUG-1996; 96US-00694579.
XX
PA (AMGE-) AMGEN INC.
PA (YEDA) YEDA RES & DEV CO LTD.
XX
PI Theill LE, Naeve GS;
XX
DR WPI; 1998-159535/14.
DR N-PSDB; AAV29022.
XX
PT New isolated neuritin gene - is used to develop products for treating
PT e.g. Alzheimer's disease, Parkinson's disease, peripheral neuropathy and
PT damaged or degenerated nervous system tissue.
XX
PS Claim 1; Fig 3; 83pp; English.
XX
CC This is the full length amino acid sequence of the rat neuritin. The gene
CC products (e.g. antibody, peptide fragments etc) can be used to treat
CC patients in whom various cells of the central, autonomic, or peripheral
CC nervous system have been degenerated, as well as treatment of e.g.
CC Alzheimer's disease, Parkinson's disease. They can also be used in
CC conjunction with surgical implantation of tissue in the treatment of
CC diseases in which tissue implantation is indicated. The products can also
CC be used for detection and diagnosis
XX
SQ Sequence 142 AA;

```
  Query Match             100.0%;  Score 480;  DB 2;  Length 142;
  Best Local Similarity   100.0%;  Pred. No. 1.3e-50;
  Matches   87;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 60
```

```
                    ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          28 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 87

Qy          61 KDMWDKLRKESKNLNIQGSLFELCGSG 87
               ||||||||||||||||||||||||||||
Db          88 KDMWDKLRKESKNLNIQGSLFELCGSG 114


RESULT 4
AAB10235
ID   AAB10235 standard; protein; 142 AA.
XX
AC   AAB10235;
XX
DT   16-NOV-2000  (first entry)
XX
DE   Human fetal brain protein fragment AS34_1i.
XX
KW   Secreted protein; cytostatic; immunostimulatory; antimicrobial;
KW   antiviral; immunosuppressive; antiinflammatory; vulnerary; cytokine;
KW   cell proliferation; differentiation; regulator; treatment; tumor;
KW   autoimmune disease; inflammatory disorder; wound; microbial infection;
KW   viral disease; graft versus host reaction suppression.
XX
OS   Homo sapiens.
XX
PN   WO200037630-A1.
XX
PD   29-JUN-2000.
XX
PF   22-DEC-1999;   99WO-US031005.
XX
PR   23-DEC-1998;   98US-00220876.
XX
PA   (GEMY ) GENETICS INST INC.
XX
PI   Jacobs K,  Mccoy JM,  Lavallie ER,  Collins-Racie LA,  Evans C;
PI   Merberg D,  Treacy M,  Bowman MR;
XX
DR   WPI; 2000-442661/38.
DR   N-PSDB; AAA40501.
XX
PT   Secreted human proteins AS296-1i and AS34-1i, useful for treating tumors,
PT   autoimmune diseases, inflammatory disorders, wounds, microbial infections
PT   and viral diseases.
XX
PS   Claim 9a; Page 209-210; 293pp; English.
XX
CC   This invention describes novel secreted human proteins (I) which have
CC   cytostatic, immunostimulatory, antimicrobial, antiviral,
CC   immunosuppressive, antiinflammatory and vulnerary activity and which act
CC   as cytokine, cell proliferation or differentiation regulators. (I) is
CC   useful for treating tumors, autoimmune diseases, inflammatory disorders,
CC   wounds, microbial infections and viral diseases. (I) is also useful for
CC   suppressing graft versus host reaction. AAB10226-B10288 represent the
CC   secreted proteins encoded by AAA40490-A40580 which are described in the
CC   method of the invention
XX
SQ   Sequence 142 AA;

  Query Match             100.0%;  Score 480;  DB 3;  Length 142;
  Best Local Similarity   100.0%;  Pred. No. 1.3e-50;
  Matches   87;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          28 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 87

Qy          61 KDMWDKLRKESKNLNIQGSLFELCGSG 87
               ||||||||||||||||||||||||||||
Db          88 KDMWDKLRKESKNLNIQGSLFELCGSG 114


RESULT 5
AAM39848
ID   AAM39848 standard; protein; 142 AA.
XX
AC   AAM39848;
XX
DT   22-OCT-2001  (first entry)
XX
DE   Human polypeptide SEQ ID NO 2993.
XX
KW   Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW   peripheral nervous system; neuropathy; central nervous system; CNS;
KW   Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW   amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW   chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW   leukaemia.
XX
OS   Homo sapiens.
XX
PN   WO200153312-A1.
XX
PD   26-JUL-2001.
XX
PF   26-DEC-2000; 2000WO-US034263.
XX
PR   23-DEC-1999;   99US-00471275.
PR   21-JAN-2000; 2000US-00488725.
PR   25-APR-2000; 2000US-00552317.
PR   20-JUN-2000; 2000US-00598042.
PR   19-JUL-2000; 2000US-00620312.
PR   03-AUG-2000; 2000US-00653450.
PR   14-SEP-2000; 2000US-00662191.
PR   19-OCT-2000; 2000US-00693036.
PR   29-NOV-2000; 2000US-00727344.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Asundi V,  Chen R,  Ma Y,  Qian XB,  Ren F,  Wang D;
PI   Wang J,  Wang Z,  Wehrman T,  Xu C,  Xue AJ,  Yang Y,  Zhang J,  Zhao QA;
PI   Zhou P,  Goodrich R,  Drmanac RT;
XX
DR   WPI; 2001-442253/47.
DR   N-PSDB; AAI59004.
XX
PT   Novel nucleic acids and polypeptides, useful for treating disorders such
PT   as central nervous system injuries.
XX
PS   Example 4; SEQ ID NO 2993; 10078pp; English.
XX
CC   The invention relates to human nucleic acids (AAI57798-AAI61369) and the
CC   encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC   immunosuppressant and cytostatic activity. The polynucleotides are useful
CC   in gene therapy. A composition containing a polypeptide or polynucleotide
CC   of the invention may be used to treat diseases of the peripheral nervous
CC   system, such as peripheral nervous injuries, peripheral neuropathy and
CC   localised neuropathies and central nervous system diseases, such as
CC   Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC   lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC   utilisation of the activities such as: Immune system suppression,
CC   Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC   and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC   assays for receptor activity, arthritis and inflammation, leukaemias and
CC   C.N.S disorders. Note: The sequence data for this patent did not form
CC   part of the printed specification
XX
SQ   Sequence 142 AA;

  Query Match             100.0%;  Score 480;  DB 4;  Length 142;
  Best Local Similarity   100.0%;  Pred. No. 1.3e-50;
  Matches   87;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db         28 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 87

Qy         61 KDMWDKLRKESKNLNIQGSLFELCGSG 87
              ||||||||||||||||||||||||||||
Db         88 KDMWDKLRKESKNLNIQGSLFELCGSG 114


RESULT 6
ADE63108
ID   ADE63108 standard; protein; 142 AA.
XX
AC   ADE63108;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Rat Protein AAB53415, SEQ ID NO 9043.
XX
KW   Rat; pain; neuronal tissue; gene therapy; spinal segmental nerve injury;
KW   chronic constriction injury; CCI; spared nerve injury; SNI; Chung.
XX
OS   Rattus norvegicus.
XX
PN   WO2003016475-A2.
XX
PD   27-FEB-2003.
XX
PF   14-AUG-2002; 2002WO-US025765.
XX
PR   14-AUG-2001; 2001US-0312147P.
PR   01-NOV-2001; 2001US-0346382P.
PR   26-NOV-2001; 2001US-0333347P.
XX
PA   (GEHO ) GEN HOSPITAL CORP.
PA   (FARB ) BAYER AG.
XX
PI   Woolf C,  D'urso D,  Befort K,  Costigan M;
XX
DR   WPI; 2003-268312/26.
DR   GENBANK; AAB53415.
XX
PT   New composition comprising two or more isolated polypeptides, useful for
PT   preparing a medicament for treating pain in an animal.
XX
PS   Claim 1; Page; 1017pp; English.
XX
CC   The invention discloses a composition comprising two or more isolated rat
CC   or human polynucleotides or a polynucleotide which represents a fragment,
CC   derivative or allelic variation of the nucleic acid sequence. Also
CC   claimed are a vector comprising the novel polynucleotide, a host cell
CC   comprising the vector, a method for identifying a nucleotide sequence
CC   which is differentially regulated in an animal subjected to pain and a
CC   kit to perform the method, an array, a method for identifying an agent
CC   that increases or decreases the expression of the polynucleotide sequence
CC   that is differentially expressed in neuronal tissue of a first animal
CC   subjected to pain, a method for identifying a compound which regulates
CC   the expression of a polynucleotide sequence which is differentially
CC   expressed in an animal subjected to pain, a method for identifying a
CC   compound that regulates the activity of one or more of the
CC   polynucleotides, a method for producing a pharmaceutical composition, a
CC   method for identifying a compound or small molecule that regulates the
CC   activity in an animal of one or more of the polypeptides given in the
CC   specification, a method for identifying a compound useful in treating
CC   pain and a pharmaceutical composition comprising the one or more
CC   polypeptides or their antibodies. The polynucleotide or the compound that
CC   modulates its activity is useful for preparing a medicament for treating
CC   pain (e.g. spinal segmental nerve injury (Chung), chronic constriction
CC   injury (CCI) and spared nerve injury (SNI)) in an animal (e.g. gene
CC   therapy). The sequence presented is a rat protein (shown in Table 2 of
CC   the specification) which is differentially expressed during pain. Note:
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic form directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX

SQ   Sequence 142 AA;

  Query Match             100.0%;  Score 480;  DB 7;  Length 142;
  Best Local Similarity   100.0%;  Pred. No. 1.3e-50;
  Matches   87;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         28 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 87

Qy         61 KDMWDKLRKESKNLNIQGSLFELCGSG 87
              ||||||||||||||||||||||||||||
Db         88 KDMWDKLRKESKNLNIQGSLFELCGSG 114


RESULT 7
ADE63114
ID   ADE63114 standard; protein; 142 AA.
XX
AC   ADE63114;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human Protein NP_057672, SEQ ID NO 9049.
XX
KW   Human; pain; neuronal tissue; gene therapy;
KW   spinal segmental nerve injury; chronic constriction injury; CCI;
KW   spared nerve injury; SNI; Chung.
XX
OS   Homo sapiens.
XX
PN   WO2003016475-A2.
XX
PD   27-FEB-2003.
XX
PF   14-AUG-2002; 2002WO-US025765.
XX
PR   14-AUG-2001; 2001US-0312147P.
PR   01-NOV-2001; 2001US-0346382P.
PR   26-NOV-2001; 2001US-0333347P.
XX
PA   (GEHO ) GEN HOSPITAL CORP.
PA   (FARB ) BAYER AG.
XX
PI   Woolf C,  D'urso D,  Befort K,  Costigan M;
XX
DR   WPI; 2003-268312/26.
DR   GENBANK; NP_057672.
XX
PT   New composition comprising two or more isolated polypeptides, useful for
PT   preparing a medicament for treating pain in an animal.
XX
PS   Claim 1; Page; 1017pp; English.
XX
CC   The invention discloses a composition comprising two or more isolated rat
CC   or human polynucleotides or a polynucleotide which represents a fragment,
CC   derivative or allelic variation of the nucleic acid sequence. Also
CC   claimed are a vector comprising the novel polynucleotide, a host cell
CC   comprising the vector, a method for identifying a nucleotide sequence
CC   which is differentially regulated in an animal subjected to pain and a
CC   kit to perform the method, an array, a method for identifying an agent
CC   that increases or decreases the expression of the polynucleotide sequence
CC   that is differentially expressed in neuronal tissue of a first animal
CC   subjected to pain, a method for identifying a compound which regulates
CC   the expression of a polynucleotide sequence which is differentially
CC   expressed in an animal subjected to pain, a method for identifying a
CC   compound that regulates the activity of one or more of the
CC   polynucleotides, a method for producing a pharmaceutical composition, a
CC   method for identifying a compound or small molecule that regulates the
CC   activity in an animal of one or more of the polypeptides given in the
CC   specification, a method for identifying a compound useful in treating
CC   pain and a pharmaceutical composition comprising the one or more
CC   polypeptides or their antibodies. The polynucleotide or the compound that
```

CC modulates its activity is useful for preparing a medicament for treating
CC pain (e.g. spinal segmental nerve injury (Chung), chronic constriction
CC injury (CCI) and spared nerve injury (SNI)) in an animal (e.g. gene
CC therapy). The sequence presented is a human protein (shown in Table 2 of
CC the specification) which is differentially expressed during pain. Note:
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic form directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 142 AA;

Query Match 100.0%; Score 480; DB 7; Length 142;
Best Local Similarity 100.0%; Pred. No. 1.3e-50;
Matches 87; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 28 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 87

Qy 61 KDMWDKLRKESKNLNIQGSLFELCGSG 87
|||||||||||||||||||||||||||
Db 88 KDMWDKLRKESKNLNIQGSLFELCGSG 114

RESULT 8
ADE63112
ID ADE63112 standard; protein; 142 AA.
XX
AC ADE63112;
XX
DT 29-JAN-2004 (first entry)
XX
DE Rat Protein AAB53415, SEQ ID NO 9047.
XX
KW Rat; pain; neuronal tissue; gene therapy; spinal segmental nerve injury;
KW chronic constriction injury; CCI; spared nerve injury; SNI; Chung.
XX
OS Rattus norvegicus.
XX
PN WO2003016475-A2.
XX
PD 27-FEB-2003.
XX
PF 14-AUG-2002; 2002WO-US025765.
XX
PR 14-AUG-2001; 2001US-0312147P.
PR 01-NOV-2001; 2001US-0346382P.
PR 26-NOV-2001; 2001US-0333347P.
XX
PA (GEHO) GEN HOSPITAL CORP.
PA (FARB) BAYER AG.
XX
PI Woolf C, D'urso D, Befort K, Costigan M;
XX
DR WPI; 2003-268312/26.
DR GENBANK; AAB53415.
XX
PT New composition comprising two or more isolated polypeptides, useful for
PT preparing a medicament for treating pain in an animal.
XX
PS Claim 1; Page; 1017pp; English.
XX
CC The invention discloses a composition comprising two or more isolated rat
CC or human polynucleotides or a polynucleotide which represents a fragment,
CC derivative or allelic variation of the nucleic acid sequence. Also
CC claimed are a vector comprising the novel polynucleotide, a host cell
CC comprising the vector, a method for identifying a nucleotide sequence
CC which is differentially regulated in an animal subjected to pain and a
CC kit to perform the method, an array, a method for identifying an agent
CC that increases or decreases the expression of the polynucleotide sequence
CC that is differentially expressed in neuronal tissue of a first animal
CC subjected to pain, a method for identifying a compound which regulates
CC the expression of a polynucleotide sequence which is differentially
CC expressed in an animal subjected to pain, a method for identifying a
CC compound that regulates the activity of one or more of the
CC polynucleotides, a method for producing a pharmaceutical composition, a
CC method for identifying a compound or small molecule that regulates the
CC activity in an animal of one or more of the polypeptides given in the
CC specification, a method for identifying a compound useful in treating
CC pain and a pharmaceutical composition comprising the one or more
CC polypeptides or their antibodies. The polynucleotide or the compound that
CC modulates its activity is useful for preparing a medicament for treating
CC pain (e.g. spinal segmental nerve injury (Chung), chronic constriction
CC injury (CCI) and spared nerve injury (SNI)) in an animal (e.g. gene
CC therapy). The sequence presented is a rat protein (shown in Table 2 of
CC the specification) which is differentially expressed during pain. Note:
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic form directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 142 AA;

Query Match 100.0%; Score 480; DB 7; Length 142;
Best Local Similarity 100.0%; Pred. No. 1.3e-50;
Matches 87; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 28 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 87

Qy 61 KDMWDKLRKESKNLNIQGSLFELCGSG 87
|||||||||||||||||||||||||||
Db 88 KDMWDKLRKESKNLNIQGSLFELCGSG 114

RESULT 9
ADE63110
ID ADE63110 standard; protein; 142 AA.
XX
AC ADE63110;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human Protein NP_057672, SEQ ID NO 9045.
XX
KW Human; pain; neuronal tissue; gene therapy;
KW spinal segmental nerve injury; chronic constriction injury; CCI;
KW spared nerve injury; SNI; Chung.
XX
OS Homo sapiens.
XX
PN WO2003016475-A2.
XX
PD 27-FEB-2003.
XX
PF 14-AUG-2002; 2002WO-US025765.
XX
PR 14-AUG-2001; 2001US-0312147P.
PR 01-NOV-2001; 2001US-0346382P.
PR 26-NOV-2001; 2001US-0333347P.
XX
PA (GEHO) GEN HOSPITAL CORP.
PA (FARB) BAYER AG.
XX
PI Woolf C, D'urso D, Befort K, Costigan M;
XX
DR WPI; 2003-268312/26.
DR GENBANK; NP_057672.
XX
PT New composition comprising two or more isolated polypeptides, useful for
PT preparing a medicament for treating pain in an animal.
XX
PS Claim 1; Page; 1017pp; English.
XX
CC The invention discloses a composition comprising two or more isolated rat
CC or human polynucleotides or a polynucleotide which represents a fragment,

CC derivative or allelic variation of the nucleic acid sequence. Also
CC claimed are a vector comprising the novel polynucleotide, a host cell
CC comprising the vector, a method for identifying a nucleotide sequence
CC which is differentially regulated in an animal subjected to pain and a
CC kit to perform the method, an array, a method for identifying an agent
CC that increases or decreases the expression of the polynucleotide sequence
CC that is differentially expressed in neuronal tissue of a first animal
CC subjected to pain, a method for identifying a compound which regulates
CC the expression of a polynucleotide sequence which is differentially
CC expressed in an animal subjected to pain, a method for identifying a
CC compound that regulates the activity of one or more of the
CC polynucleotides, a method for producing a pharmaceutical composition, a
CC method for identifying a compound or small molecule that regulates the
CC activity in an animal of one or more of the polypeptides given in the
CC specification, a method for identifying a compound useful in treating
CC pain and a pharmaceutical composition comprising the one or more
CC polypeptides or their antibodies. The polynucleotide or the compound that
CC modulates its activity is useful for preparing a medicament for treating
CC pain (e.g. spinal segmental nerve injury (Chung), chronic constriction
CC injury (CCI) and spared nerve injury (SNI)) in an animal (e.g. gene
CC therapy). The sequence presented is a human protein (shown in Table 2 of
CC the specification) which is differentially expressed during pain. Note:
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic form directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 142 AA;

```
  Query Match             100.0%;  Score 480;  DB 7;  Length 142;
  Best Local Similarity   100.0%;  Pred. No. 1.3e-50;
  Matches   87;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         28 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 87

Qy         61 KDMWDKLRKESKNLNIQGSLFELCGSG 87
              |||||||||||||||||||||||||||
Db         88 KDMWDKLRKESKNLNIQGSLFELCGSG 114
```

RESULT 10
ADN04842
ID ADN04842 standard; protein; 142 AA.
XX
AC ADN04842;
XX
DT 01-JUL-2004 (first entry)
XX
DE Antipsoriatic protein sequence #601.
XX
KW antipsoriatic; gene therapy; psoriasis; diagnosis.
XX
OS Homo sapiens.
XX
PN WO2004028479-A2.
XX
PD 08-APR-2004.
XX
PF 25-SEP-2003; 2003WO-US030907.
XX
PR 25-SEP-2002; 2002US-0414006P.
XX
PA (GETH) GENENTECH INC.
XX
PI Bodary S, Clark H, Jackman J, Schoenfeld J, Williams PM, Wood WI;
PI Wu TD;
XX
DR WPI; 2004-305105/28.
DR N-PSDB; ADN04841.
XX
PT New PRO nucleic acid or polypeptide, useful for preparing a
PT pharmaceutical composition for diagnosing or treating psoriasis in a
PT mammal.
XX
PS Claim 9; SEQ ID NO 1236; 3069pp; English.
XX
CC The invention relates to novel polynucleotide and polypeptides for
CC treating psoriasis or a sequence having at least 80% identity to the
CC above sequences. The nucleic acid is useful for preparing a composition
CC for diagnosing or treating psoriasis in a mammal. This sequence
CC corresponds to one of the polypeptides of the invention.
XX
SQ Sequence 142 AA;

```
  Query Match             100.0%;  Score 480;  DB 8;  Length 142;
  Best Local Similarity   100.0%;  Pred. No. 1.3e-50;
  Matches   87;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         28 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 87

Qy         61 KDMWDKLRKESKNLNIQGSLFELCGSG 87
              |||||||||||||||||||||||||||
Db         88 KDMWDKLRKESKNLNIQGSLFELCGSG 114
```

RESULT 11
AAM41634
ID AAM41634 standard; protein; 154 AA.
XX
AC AAM41634;
XX
DT 22-OCT-2001 (first entry)
XX
DE Human polypeptide SEQ ID NO 6565.
XX
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia.
XX
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001.
XX
PF 26-DEC-2000; 2000WO-US034263.
XX
PR 23-DEC-1999; 99US-00471275.
PR 21-JAN-2000; 2000US-00488725.
PR 25-APR-2000; 2000US-00552317.
PR 20-JUN-2000; 2000US-00598042.
PR 19-JUL-2000; 2000US-00620312.
PR 03-AUG-2000; 2000US-00653450.
PR 14-SEP-2000; 2000US-00662191.
PR 19-OCT-2000; 2000US-00693036.
PR 29-NOV-2000; 2000US-00727344.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J, Zhao QA;
PI Zhou P, Goodrich R, Drmanac RT;
XX
DR WPI; 2001-442253/47.
DR N-PSDB; AAI60790.
XX
PT Novel nucleic acids and polypeptides, useful for treating disorders such
PT as central nervous system injuries.
XX
PS Example 2; SEQ ID NO 6565; 10078pp; English.

```
XX
CC   The invention relates to human nucleic acids (AAI57798-AAI61369) and the
CC   encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC   immunosuppressant and cytostatic activity. The polynucleotides are useful
CC   in gene therapy. A composition containing a polypeptide or polynucleotide
CC   of the invention may be used to treat diseases of the peripheral nervous
CC   system, such as peripheral nervous injuries, peripheral neuropathy and
CC   localised neuropathies and central nervous system diseases, such as
CC   Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC   lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC   utilisation of the activities such as: Immune system suppression,
CC   Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC   and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC   assays for receptor activity, arthritis and inflammation, leukaemias and
CC   C.N.S disorders. Note: The sequence data for this patent did not form
CC   part of the printed specification
XX
SQ   Sequence 154 AA;

  Query Match             100.0%;  Score 480;  DB 4;  Length 154;
  Best Local Similarity   100.0%;  Pred. No. 1.4e-50;
  Matches   87;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         40 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 99

Qy         61 KDMWDKLRKESKNLNIQGSLFELCGSG 87
              |||||||||||||||||||||||||||
Db        100 KDMWDKLRKESKNLNIQGSLFELCGSG 126


RESULT 12
AAW89078
ID   AAW89078 standard; protein; 143 AA.
XX
AC   AAW89078;
XX
DT   01-MAR-1999  (first entry)
XX
DE   Polypeptide fragment encoded by gene 192.
XX
KW   Human; secreted protein; fusion protein; gene therapy; protein therapy;
KW   diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;
KW   developmental abnormality; foetal deficiency; blood; allergy; renal;
KW   immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;
KW   inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;
KW   cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;
KW   osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;
KW   endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.
XX
OS   Homo sapiens.
XX
PN   WO9854963-A2.
XX
PD   10-DEC-1998.
XX
PF   04-JUN-1998;   98WO-US011422.
XX
PR   06-JUN-1997;   97US-0048875P.
PR   06-JUN-1997;   97US-0048876P.
PR   06-JUN-1997;   97US-0048877P.
PR   06-JUN-1997;   97US-0048878P.
PR   06-JUN-1997;   97US-0048880P.
PR   06-JUN-1997;   97US-0048881P.
PR   06-JUN-1997;   97US-0048882P.
PR   06-JUN-1997;   97US-0048883P.
PR   06-JUN-1997;   97US-0048884P.
PR   06-JUN-1997;   97US-0048885P.
PR   06-JUN-1997;   97US-0048892P.
PR   06-JUN-1997;   97US-0048893P.
PR   06-JUN-1997;   97US-0048894P.
PR   06-JUN-1997;   97US-0048895P.
PR   06-JUN-1997;   97US-0048896P.
PR   06-JUN-1997;   97US-0048897P.
PR   06-JUN-1997;   97US-0048898P.
PR   06-JUN-1997;   97US-0048899P.
PR   06-JUN-1997;   97US-0048900P.
PR   06-JUN-1997;   97US-0048901P.
PR   06-JUN-1997;   97US-0048915P.
PR   06-JUN-1997;   97US-0048916P.
PR   06-JUN-1997;   97US-0048917P.
PR   06-JUN-1997;   97US-0048949P.
PR   06-JUN-1997;   97US-0048962P.
PR   06-JUN-1997;   97US-0048963P.
PR   06-JUN-1997;   97US-0048964P.
PR   06-JUN-1997;   97US-0048970P.
PR   06-JUN-1997;   97US-0048971P.
PR   06-JUN-1997;   97US-0048972P.
PR   06-JUN-1997;   97US-0048974P.
PR   06-JUN-1997;   97US-0049019P.
PR   06-JUN-1997;   97US-0049020P.
PR   06-JUN-1997;   97US-0049373P.
PR   06-JUN-1997;   97US-0049374P.
PR   06-JUN-1997;   97US-0049375P.
PR   05-SEP-1997;   97US-0057584P.
PR   05-SEP-1997;   97US-0057627P.
PR   05-SEP-1997;   97US-0057628P.
PR   05-SEP-1997;   97US-0057629P.
PR   05-SEP-1997;   97US-0057634P.
PR   05-SEP-1997;   97US-0057635P.
PR   05-SEP-1997;   97US-0057642P.
PR   05-SEP-1997;   97US-0057643P.
PR   05-SEP-1997;   97US-0057644P.
PR   05-SEP-1997;   97US-0057645P.
PR   05-SEP-1997;   97US-0057646P.
PR   05-SEP-1997;   97US-0057647P.
PR   05-SEP-1997;   97US-0057648P.
PR   05-SEP-1997;   97US-0057649P.
PR   05-SEP-1997;   97US-0057650P.
PR   05-SEP-1997;   97US-0057651P.
PR   05-SEP-1997;   97US-0057654P.
PR   05-SEP-1997;   97US-0057661P.
PR   05-SEP-1997;   97US-0057662P.
PR   05-SEP-1997;   97US-0057666P.
PR   05-SEP-1997;   97US-0057667P.
PR   05-SEP-1997;   97US-0057668P.
PR   05-SEP-1997;   97US-0057760P.
PR   05-SEP-1997;   97US-0057761P.
PR   05-SEP-1997;   97US-0057762P.
PR   05-SEP-1997;   97US-0057763P.
PR   05-SEP-1997;   97US-0057764P.
PR   05-SEP-1997;   97US-0057765P.
PR   05-SEP-1997;   97US-0057769P.
PR   05-SEP-1997;   97US-0057770P.
PR   05-SEP-1997;   97US-0057771P.
PR   05-SEP-1997;   97US-0057774P.
PR   05-SEP-1997;   97US-0057775P.
PR   05-SEP-1997;   97US-0057776P.
PR   05-SEP-1997;   97US-0057777P.
PR   05-SEP-1997;   97US-0057778P.
PR   18-DEC-1997;   97US-0070923P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Young P,  Greene JM,  Ferrie AM,  Ruben SM,  Rosen CA,  Hu J;
PI   Olsen HS,  Ebner R,  Brewer LA,  Moore PA,  Shi Y,  Florence C;
PI   Florence K,  Lafleur DW,  Ni J,  Fan P,  Wei Y,  Fischer CL,  Soppet DR;
PI   Li Y,  Zeng Z,  Kyaw H,  Yu G,  Feng P,  Dillon PJ,  Endress GA;
PI   Carter KC;
XX
DR   WPI; 1999-059865/05.
DR   N-PSDB; AAV84602.
XX
PT   New isolated human genes and the secreted polypeptides they encode -
PT   useful for diagnosis and treatment of e.g. cancers, neurological
```

PT disorders, immune diseases, inflammation or blood disorders.
XX
PS Disclosure; Page 149; 772pp; English.
XX
CC The invention relates to nucleic acid sequences (AAV84411 to AAV84633)
CC encoding human secreted proteins (AAW88534 to AAW88756). The secreted
CC protein gene sequences are deposited with the ATCC under deposit numbers
CC ATCC 97979, 97974, 97975, 97976, 97977, 209007, 209008, 209009, 209010,
CC 209011, 209080, 209081, 209082, 209083, 209084, 209085, 209511. Host
CC cells comprising recombinant vectors containing the nucleic acid
CC sequences are used for the recombinant production of the secreted
CC proteins. The polynucleotide and amino acid sequences are useful for are
CC useful for preventing, treating or ameliorating medical conditions e.g.
CC by protein or gene therapy. Pathological conditions can be also diagnosed
CC by determining the amount of the new polypeptides in a sample or by
CC determining the presence of mutations in the new polynucleotides.
CC Specific uses are described for each of the polynucleotides, based on
CC which tissues they are most highly expressed in, and include developing
CC products for the diagnosis or treatment of cancer, neurodegenerative
CC disorders, developmental abnormalities and foetal deficiencies, blood
CC disorders, tumours, leukemias, diseases of the immune system, autoimmune
CC diseases, hepatic and renal disease, lymphomas, inflammation, allergies,
CC ischemic shock, Alzheimer's and cognitive disorders, schizophrenia,
CC restenosis, prostate diseases, obesity, disorders involving osteoclasts
CC such as osteoporosis, arthritis or malignancies, diseases of testes, lung
CC or thymus, digestive/endocrine disorders, infections and AIDS. The
CC polypeptides are also useful for identifying their binding partners. The
CC present sequence represents a polypeptide fragment encoded by a gene of
CC the invention (see descriptor line for gene number)
XX
SQ Sequence 143 AA;

Query Match 88.9%; Score 426.5; DB 2; Length 143;
Best Local Similarity 90.9%; Pred. No. 5e-44;
Matches 80; Conservative 0; Mismatches 7; Indels 1; Gaps 1;

Qy 1 AGKCDAVFKGFSDCLLKLGDS-MANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEG 59
||||||||||||||||||||| | ||||||||||||||||||||||||||||
Db 28 AGKCDAVFKGFSDCLLKLGDSXXXXXPAAWDDKTNIKTVCTYWEDFHSCTVTALTDCQEG 87

Qy 60 AKDMWDKLRKESKNLNIQGSLFELCGSG 87
|||||||||||||||||||||||||||||
Db 88 AKDMWDKLRKESKNLNIQGSLFELCGSG 115

RESULT 13
ABB51249
ID ABB51249 standard; protein; 143 AA.
XX
AC ABB51249;
XX
DT 07-FEB-2002 (first entry)
XX
DE Human secreted protein encoded by gene 192 SEQ ID NO:1202.
XX
KW Human; secreted protein; immunomodulatory; antisclerotic; anti-HIV;
KW dermatological; immunosuppressive; antiinflammatory; immunostimulant;
KW cytostatic; cardiant; vascular; anti-angiogenic; ophthalmological;
KW neuroprotective; nootropic; anticonvulsant; antialzheimers; vulnerary;
KW antiparkinsonian; antimicrobial; gene therapy; vaccine; immune disorder;
KW multiple sclerosis; systemic lupus erythematosus; HIV infection; cancer;
KW human immunodeficiency virus; hyperproliferative disorder; wound healing;
KW Gaucher's disease; cardiovascular disease; Scimitar syndrome; chemotaxis;
KW Chaga's cardiomyopathy; coronary arteriosclerosis; angiogenic disorder;
KW corneal graft neovascularisation; diabetic retinopathy; regeneration;
KW neurological disorder; Huntington's chorea; Alzheimer's disease;
KW Parkinson's disease; infectious disease; chromosome 6.
XX
OS Homo sapiens.
XX
PN WO200162891-A2.
XX
PD 30-AUG-2001.
XX
PF 21-FEB-2001; 2001WO-US005614.
XX
PR 24-FEB-2000; 2000US-0184836P.
PR 29-MAR-2000; 2000US-0193170P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ni J, Ebner R, Lafleur DW, Moore PA, Olsen HS, Rosen CA;
PI Ruben SM, Soppet DR, Young PE, Shi Y, Florence KA, Wei Y;
PI Florence C, Hu J, Li Y, Kyaw H, Fischer CL, Ferrie AM, Fan P;
PI Feng P, Endress GA, Dillon PJ, Carter KC, Brewer LA, Yu G, Zeng Z;
PI Greene JM;
XX
DR WPI; 2001-625724/72.
XX
PT Nucleic acids encoding 207 human secreted polypeptides, useful for
PT preventing, diagnosing and/or treating, e.g. cancers, Parkinson's disease
PT and diabetic retinopathy.
XX
PS Disclosure; Page 414; 1533pp; English.
XX
CC ABB50301 to ABB51287 and ABA83194 to ABA83441 represent human secreted
CC proteins (I) and polynucleotide (II) sequences. (I) and (II) have various
CC activities based on the tissues and cells the genes are expressed in.
CC Example of these activities include: immunomodulatory; antisclerotic;
CC dermatological; immunosuppressive; antiinflammatory; immunostimulant;
CC anti-HIV; cytostatic; cardiant; anti-angiogenic; ophthalmological;
CC neuroprotective; nootropic; anticonvulsant; antialzheimers; vascular;
CC antiparkinsonian; antimicrobial; and vulnerary. (I) and (II) can be used
CC in gene therapy and vaccine production. (I) and (II) can be used in the
CC prevention, diagnosis and treatment of immune disorders (e.g. multiple
CC sclerosis, systemic lupus erythematosus and human immunodeficiency virus
CC (HIV) infections), hyperproliferative disorders (e.g. cancers and
CC Gaucher's disease), cardiovascular diseases (e.g. Scimitar syndrome,
CC Chaga's cardiomyopathy and coronary arteriosclerosis), angiogenic
CC disorders (e.g. corneal graft neovascularisation and diabetic
CC retinopathy), neurological disorders (e.g. Huntington's chorea,
CC Alzheimer's disease and Parkinson's disease), infectious diseases and/or
CC for promoting wound healing, regeneration and/or chemotaxis. ABA83185 to
CC ABA83193 and ABB50300 represent sequences used in the exemplification of
CC the present invention
XX
SQ Sequence 143 AA;

Query Match 88.9%; Score 426.5; DB 4; Length 143;
Best Local Similarity 90.9%; Pred. No. 5e-44;
Matches 80; Conservative 0; Mismatches 7; Indels 1; Gaps 1;

Qy 1 AGKCDAVFKGFSDCLLKLGDS-MANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEG 59
||||||||||||||||||||| | ||||||||||||||||||||||||||||
Db 28 AGKCDAVFKGFSDCLLKLGDSXXXXXPAAWDDKTNIKTVCTYWEDFHSCTVTALTDCQEG 87

Qy 60 AKDMWDKLRKESKNLNIQGSLFELCGSG 87
|||||||||||||||||||||||||||||
Db 88 AKDMWDKLRKESKNLNIQGSLFELCGSG 115

RESULT 14
ABO45506
ID ABO45506 standard; protein; 143 AA.
XX
AC ABO45506;
XX
DT 03-OCT-2003 (first entry)
XX
DE Novel human secreted protein #192 fragment #6.
XX
KW Human; gene therapy; autoimmune disorder; multiple sclerosis; cancer;
KW systemic lupus erythematosus; haematopoietic cell disorder; allergy;
KW agammaglobulinaemia; ataxia telangiectasia; blood coagulation disorder;
KW afibrinogenaemia; thrombocytopenia; graft-versus-host disease; arthritis;
KW inflammatory condition; ischaemia-reperfusion injury; infectious disease;

KW hyperproliferative disorder; purpura; viral infection; regeneration;
KW bacterial infection; ulcer; Alzheimer's disease.
XX
OS Homo sapiens.
XX
PN US2003065160-A1.
XX
PD 03-APR-2003.
XX
PF 07-DEC-2001; 2001US-00004860.
XX
PR 06-JUN-1997; 97US-0048875P.
PR 06-JUN-1997; 97US-0048876P.
PR 06-JUN-1997; 97US-0048877P.
PR 06-JUN-1997; 97US-0048878P.
PR 06-JUN-1997; 97US-0048880P.
PR 06-JUN-1997; 97US-0048881P.
PR 06-JUN-1997; 97US-0048882P.
PR 06-JUN-1997; 97US-0048883P.
PR 06-JUN-1997; 97US-0048884P.
PR 06-JUN-1997; 97US-0048885P.
PR 06-JUN-1997; 97US-0048892P.
PR 06-JUN-1997; 97US-0048893P.
PR 06-JUN-1997; 97US-0048894P.
PR 06-JUN-1997; 97US-0048895P.
PR 06-JUN-1997; 97US-0048896P.
PR 06-JUN-1997; 97US-0048897P.
PR 06-JUN-1997; 97US-0048898P.
PR 06-JUN-1997; 97US-0048899P.
PR 06-JUN-1997; 97US-0048900P.
PR 06-JUN-1997; 97US-0048901P.
PR 06-JUN-1997; 97US-0048915P.
PR 06-JUN-1997; 97US-0048916P.
PR 06-JUN-1997; 97US-0048917P.
PR 06-JUN-1997; 97US-0048949P.
PR 06-JUN-1997; 97US-0048962P.
PR 06-JUN-1997; 97US-0048963P.
PR 06-JUN-1997; 97US-0048964P.
PR 06-JUN-1997; 97US-0048970P.
PR 06-JUN-1997; 97US-0048971P.
PR 06-JUN-1997; 97US-0048972P.
PR 06-JUN-1997; 97US-0048974P.
PR 06-JUN-1997; 97US-0049019P.
PR 06-JUN-1997; 97US-0049020P.
PR 06-JUN-1997; 97US-0049373P.
PR 06-JUN-1997; 97US-0049374P.
PR 06-JUN-1997; 97US-0049375P.
PR 05-SEP-1997; 97US-0057584P.
PR 05-SEP-1997; 97US-0057627P.
PR 05-SEP-1997; 97US-0057628P.
PR 05-SEP-1997; 97US-0057629P.
PR 05-SEP-1997; 97US-0057634P.
PR 05-SEP-1997; 97US-0057635P.
PR 05-SEP-1997; 97US-0057642P.
PR 05-SEP-1997; 97US-0057643P.
PR 05-SEP-1997; 97US-0057644P.
PR 05-SEP-1997; 97US-0057645P.
PR 05-SEP-1997; 97US-0057646P.
PR 05-SEP-1997; 97US-0057647P.
PR 05-SEP-1997; 97US-0057648P.
PR 05-SEP-1997; 97US-0057649P.
PR 05-SEP-1997; 97US-0057650P.
PR 05-SEP-1997; 97US-0057651P.
PR 05-SEP-1997; 97US-0057654P.
PR 05-SEP-1997; 97US-0057661P.
PR 05-SEP-1997; 97US-0057662P.
PR 05-SEP-1997; 97US-0057666P.
PR 05-SEP-1997; 97US-0057667P.
PR 05-SEP-1997; 97US-0057668P.
PR 05-SEP-1997; 97US-0057760P.
PR 05-SEP-1997; 97US-0057761P.
PR 05-SEP-1997; 97US-0057762P.
PR 05-SEP-1997; 97US-0057763P.
PR 05-SEP-1997; 97US-0057764P.
PR 05-SEP-1997; 97US-0057765P.
PR 05-SEP-1997; 97US-0057769P.
PR 05-SEP-1997; 97US-0057770P.
PR 05-SEP-1997; 97US-0057771P.
PR 05-SEP-1997; 97US-0057774P.
PR 05-SEP-1997; 97US-0057775P.
PR 05-SEP-1997; 97US-0057776P.
PR 05-SEP-1997; 97US-0057777P.
PR 05-SEP-1997; 97US-0057778P.
PR 18-DEC-1997; 97US-0070923P.
PR 04-JUN-1998; 98WO-US011422.
PR 15-JUL-1998; 98US-0092921P.
PR 30-JUL-1998; 98US-0094657P.
PR 04-DEC-1998; 98US-00205258.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Young P, Greene JM, Ferrie AM, Ruben SM, Rosen CA, Hu J;
PI Olsen HS, Ebner R, Brewer LA, Moore PA, Shi Y, Florence C;
PI Florence K, Lafleur DW, Ni J, Fan P, Wei Y, Fischer CL, Soppet DR;
PI Li Y, Zeng Z, Kyaw H, Yu G, Feng P, Dillon PJ, Endress GA;
PI Carter KC;
XX
DR WPI; 2003-540804/51.
XX
PT New isolated protein, useful for preparing a composition for diagnosing
PT or treating cancer, inflammatory, immune or infectious diseases.
XX
PS Disclosure; Page 117; 172pp; English.
XX
CC The invention relates to an isolated HEMAE80 protein. The protein is
CC useful for preparing a composition for diagnosing or treating autoimmune
CC disorders e.g. multiple sclerosis and systemic lupus erythematosus;
CC haematopoietic cell disorders e.g. agammaglobulinaemia and ataxia
CC telangiectasia; blood coagulation disorders e.g. afibrinogenaemia and
CC thrombocytopenia; allergy; graft-versus-host disease; inflammatory
CC conditions e.g. ischaemia-reperfusion injury and arthritis;
CC hyperproliferative disorders e.g. cancer and purpura; infectious disease
CC e.g. viral infection and bacterial infection. The polynucleotide or
CC protein can be used to regenerate damaged tissue e.g. ulcers and
CC Alzheimer's disease. The present sequence represents the amino acid
CC sequence of a novel human secreted protein fragment. Note: The sequence
CC data for this patent did not form part of the printed specification but
CC was obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html?DocID=20030065160
XX
SQ Sequence 143 AA;

Query Match 88.9%; Score 426.5; DB 6; Length 143;
Best Local Similarity 90.9%; Pred. No. 5e-44;
Matches 80; Conservative 0; Mismatches 7; Indels 1; Gaps 1;

```
Qy          1 AGKCDAVFKGFSDCLLKLGDS-MANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEG 59
              |||||||||||||||||||||      |   |||||||||||||||||||||||||||||
Db         28 AGKCDAVFKGFSDCLLKLGDSXXXXXPAAWDDKTNIKTVCTYWEDFHSCTVTALTDCQEG 87

Qy         60 AKDMWDKLRKESKNLNIQGSLFELCGSG 87
              ||||||||||||||||||||||||||||
Db         88 AKDMWDKLRKESKNLNIQGSLFELCGSG 115
```

RESULT 15
ABO26986
ID ABO26986 standard; protein; 143 AA.
XX
AC ABO26986;
XX
DT 10-SEP-2003 (first entry)
XX
DE Protein associated with novel secreted protein gene 192 #6.
XX
KW Secreted protein; precerebellin-like protein; sepsis; acne; psoriasis;

KW neurodegenerative disorder; behavioural disorder; Alzheimer's disease;
KW Parkinson's disease; Huntington's disease; schizophrenia; mania;
KW dementia; paranoia; psychosis; autism; immune disorder; infection;
KW inflammation; allergy; liver disorder; hepatoblastoma; jaundice;
KW hepatitis; immunological disorder; AIDS; leukaemia; rheumatoid arthritis;
KW cancer.
XX
OS Unidentified.
XX
PN US6525174-B1.
XX
PD 25-FEB-2003.
XX
PF 04-DEC-1998; 98US-00205258.
XX
PR 06-JUN-1997; 97US-0048875P.
PR 06-JUN-1997; 97US-0048876P.
PR 06-JUN-1997; 97US-0048877P.
PR 06-JUN-1997; 97US-0048878P.
PR 06-JUN-1997; 97US-0048880P.
PR 06-JUN-1997; 97US-0048881P.
PR 06-JUN-1997; 97US-0048882P.
PR 06-JUN-1997; 97US-0048883P.
PR 06-JUN-1997; 97US-0048884P.
PR 06-JUN-1997; 97US-0048885P.
PR 06-JUN-1997; 97US-0048892P.
PR 06-JUN-1997; 97US-0048893P.
PR 06-JUN-1997; 97US-0048894P.
PR 06-JUN-1997; 97US-0048895P.
PR 06-JUN-1997; 97US-0048896P.
PR 06-JUN-1997; 97US-0048897P.
PR 06-JUN-1997; 97US-0048898P.
PR 06-JUN-1997; 97US-0048899P.
PR 06-JUN-1997; 97US-0048900P.
PR 06-JUN-1997; 97US-0048901P.
PR 06-JUN-1997; 97US-0048915P.
PR 06-JUN-1997; 97US-0048916P.
PR 06-JUN-1997; 97US-0048917P.
PR 06-JUN-1997; 97US-0048949P.
PR 06-JUN-1997; 97US-0048962P.
PR 06-JUN-1997; 97US-0048963P.
PR 06-JUN-1997; 97US-0048964P.
PR 06-JUN-1997; 97US-0048970P.
PR 06-JUN-1997; 97US-0048971P.
PR 06-JUN-1997; 97US-0048972P.
PR 06-JUN-1997; 97US-0048974P.
PR 06-JUN-1997; 97US-0049019P.
PR 06-JUN-1997; 97US-0049020P.
PR 06-JUN-1997; 97US-0049373P.
PR 06-JUN-1997; 97US-0049374P.
PR 06-JUN-1997; 97US-0049375P.
PR 05-SEP-1997; 97US-0057584P.
PR 05-SEP-1997; 97US-0057627P.
PR 05-SEP-1997; 97US-0057628P.
PR 05-SEP-1997; 97US-0057629P.
PR 05-SEP-1997; 97US-0057634P.
PR 05-SEP-1997; 97US-0057635P.
PR 05-SEP-1997; 97US-0057642P.
PR 05-SEP-1997; 97US-0057643P.
PR 05-SEP-1997; 97US-0057644P.
PR 05-SEP-1997; 97US-0057645P.
PR 05-SEP-1997; 97US-0057646P.
PR 05-SEP-1997; 97US-0057647P.
PR 05-SEP-1997; 97US-0057648P.
PR 05-SEP-1997; 97US-0057649P.
PR 05-SEP-1997; 97US-0057650P.
PR 05-SEP-1997; 97US-0057651P.
PR 05-SEP-1997; 97US-0057654P.
PR 05-SEP-1997; 97US-0057661P.
PR 05-SEP-1997; 97US-0057662P.
PR 05-SEP-1997; 97US-0057666P.
PR 05-SEP-1997; 97US-0057667P.
PR 05-SEP-1997; 97US-0057668P.
PR 05-SEP-1997; 97US-0057760P.
PR 05-SEP-1997; 97US-0057761P.
PR 05-SEP-1997; 97US-0057762P.
PR 05-SEP-1997; 97US-0057763P.
PR 05-SEP-1997; 97US-0057764P.
PR 05-SEP-1997; 97US-0057765P.
PR 05-SEP-1997; 97US-0057769P.
PR 05-SEP-1997; 97US-0057770P.
PR 05-SEP-1997; 97US-0057771P.
PR 05-SEP-1997; 97US-0057774P.
PR 05-SEP-1997; 97US-0057775P.
PR 05-SEP-1997; 97US-0057776P.
PR 05-SEP-1997; 97US-0057777P.
PR 05-SEP-1997; 97US-0057778P.
PR 18-DEC-1997; 97US-0070923P.
PR 04-JUN-1998; 98WO-US011422.
PR 15-JUL-1998; 98US-0092921P.
PR 30-JUL-1998; 98US-0094657P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Young P, Greene JM, Ferrie AM, Ruben SM, Rosen CA, Hu J;
PI Olsen HS, Ebner R, Brewer LA, Moore PA, Shi Y, Florence C;
PI Florence K, Lafleur DW, Ni J, Fan P, Wei Y, Fischer CL, Soppet DR;
PI Li Y, Zeng Z, Kyaw H, Yu G, Feng P, Dillon PJ, Endress GA;
PI Carter KC;
XX
DR WPI; 2003-511926/48.
XX
PT New precerebellin-like protein, useful for diagnosing or treating
PT neurodegenerative and behavioral disorders, immune disorders, liver
PT disorders, and cancer.
XX
PS Disclosure; Col 213; 156pp; English.
XX
CC The invention relates to an isolated protein comprising amino acid
CC residues 33-205 or 1-205 of a a novel human secreted protein appearing as
CC ABO26252. The protein is encoded by one of 238 disclosed cDNA sequences
CC encoding 238 secreted proteins. ABO26252 is a precerebellin-like protein.
CC Also included are a composition comprising the protein and a carrier and
CC an isolated protein produced by expressing the protein cited above by a
CC cell, and recovering the protein. The proteins are useful for diagnosing
CC or treating neurodegenerative and behavioural disorders (e.g. Alzheimer's
CC disease, Parkinson's disease, Huntington's disease, schizophrenia, mania,
CC dementia, paranoia, psychoses or autism), immune disorders (e.g.
CC infection, inflammation, allergy), liver disorders (e.g. hepatoblastoma,
CC jaundice, hepatitis), immunological disorders (e.g. AIDS, leukaemia,
CC rheumatoid arthritis, sepsis, acne, psoriasis) and cancer. The present
CC sequence is a protein associated with one of the 238 disclosed novel
CC secreted proteins
XX
SQ Sequence 143 AA;

Query Match 88.9%; Score 426.5; DB 7; Length 143;
Best Local Similarity 90.9%; Pred. No. 5e-44;
Matches 80; Conservative 0; Mismatches 7; Indels 1; Gaps 1;

```
Qy          1 AGKCDAVFKGFSDCLLKLGDS-MANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEG 59
              |||||||||||||||||||||      |   |||||||||||||||||||||||||||
Db         28 AGKCDAVFKGFSDCLLKLGDSXXXXXPAAWDDKTNIKTVCTYWEDFHSCTVTALTDCQEG 87

Qy         60 AKDMWDKLRKESKNLNIQGSLFELCGSG 87
              ||||||||||||||||||||||||||||
Db         88 AKDMWDKLRKESKNLNIQGSLFELCGSG 115
```

Search completed: December 20, 2004, 15:19:54
Job time : 78 secs

OM protein - protein search, using sw model

Run on: December 20, 2004, 15:18:36 ; Search time 144 Seconds
(without alignments)
216.192 Million cell updates/sec

Title: US-10-670-911A-1
Perfect score: 480
Sequence: 1 AGKCDAVFKGFSDCLLKLGD.....RKESKNLNIQGSLFELCGSG 87

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1589859 seqs, 357834939 residues

Total number of hits satisfying chosen parameters: 1589859

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published_Applications_AA:*
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep:*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep:*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep:*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep:*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep:*
6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep:*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep:*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep:*
9: /cgn2_6/ptodata/1/pubpaa/US09A_PUBCOMB.pep:*
10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep:*
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep:*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep:*
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep:*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep:*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep:*
16: /cgn2_6/ptodata/1/pubpaa/US10D_PUBCOMB.pep:*
17: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep:*
18: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep:*
19: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep:*
20: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	480	100.0	87	16	US-10-670-911A-1	Sequence 1, Appli
2	426.5	88.9	143	10	US-09-933-767-1202	Sequence 1202, Ap
3	426.5	88.9	143	14	US-10-004-860-1202	Sequence 1202, Ap
4	426.5	88.9	143	14	US-10-023-282-1202	Sequence 1202, Ap
5	327	68.1	90	10	US-09-933-767-1201	Sequence 1201, Ap
6	327	68.1	90	14	US-10-004-860-1201	Sequence 1201, Ap
7	327	68.1	90	14	US-10-023-282-1201	Sequence 1201, Ap
8	179.5	37.4	165	13	US-10-001-054-44	Sequence 44, Appl
9	179.5	37.4	165	14	US-10-227-884-230	Sequence 230, App
10	179.5	37.4	165	14	US-10-230-163-230	Sequence 230, App
11	179.5	37.4	165	14	US-10-230-338-230	Sequence 230, App
12	179.5	37.4	165	14	US-10-218-631-230	Sequence 230, App
13	179.5	37.4	165	14	US-10-230-414-230	Sequence 230, App
14	179.5	37.4	165	14	US-10-232-224-230	Sequence 230, App
15	179.5	37.4	165	14	US-10-216-159A-230	Sequence 230, App
16	179.5	37.4	165	14	US-10-218-849-230	Sequence 230, App
17	179.5	37.4	165	14	US-10-227-873-230	Sequence 230, App
18	179.5	37.4	165	14	US-10-227-883-230	Sequence 230, App
19	179.5	37.4	165	14	US-10-219-076-230	Sequence 230, App
20	179.5	37.4	165	14	US-10-230-434-230	Sequence 230, App
21	179.5	37.4	165	14	US-10-219-003-230	Sequence 230, App
22	179.5	37.4	165	14	US-10-219-075-230	Sequence 230, App
23	179.5	37.4	165	14	US-10-219-464-230	Sequence 230, App
24	179.5	37.4	165	14	US-10-219-466-230	Sequence 230, App
25	179.5	37.4	165	14	US-10-219-479-230	Sequence 230, App
26	179.5	37.4	165	14	US-10-219-481-230	Sequence 230, App
27	179.5	37.4	165	14	US-10-230-260-230	Sequence 230, App
28	179.5	37.4	165	14	US-10-232-231-230	Sequence 230, App
29	179.5	37.4	165	14	US-10-232-233-230	Sequence 230, App
30	179.5	37.4	165	14	US-10-216-165-230	Sequence 230, App
31	179.5	37.4	165	14	US-10-218-956-230	Sequence 230, App
32	179.5	37.4	165	14	US-10-219-468-230	Sequence 230, App
33	179.5	37.4	165	14	US-10-219-478-230	Sequence 230, App
34	179.5	37.4	165	14	US-10-219-536-230	Sequence 230, App
35	179.5	37.4	165	14	US-10-233-205-230	Sequence 230, App
36	179.5	37.4	165	14	US-10-219-072-230	Sequence 230, App
37	179.5	37.4	165	14	US-10-219-470-230	Sequence 230, App
38	179.5	37.4	165	14	US-10-219-474-230	Sequence 230, App
39	179.5	37.4	165	14	US-10-219-524-230	Sequence 230, App
40	179.5	37.4	165	14	US-10-219-528-230	Sequence 230, App
41	179.5	37.4	165	14	US-10-227-880-230	Sequence 230, App
42	179.5	37.4	165	14	US-10-227-881-230	Sequence 230, App
43	179.5	37.4	165	14	US-10-227-882-230	Sequence 230, App
44	179.5	37.4	165	14	US-10-230-436-230	Sequence 230, App
45	179.5	37.4	165	14	US-10-232-223-230	Sequence 230, App

ALIGNMENTS

RESULT 1
US-10-670-911A-1
; Sequence 1, Application US/10670911A
; Publication No. US20040176291A1
; GENERAL INFORMATION:
; APPLICANT: Nedivi, Elly
; APPLICANT: Putz, Ulrich
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR SOLUBLE CPG
; FILE REFERENCE: 01997/547002
; CURRENT APPLICATION NUMBER: US/10/670,911A
; CURRENT FILING DATE: 2003-09-24
; PRIOR APPLICATION NUMBER: US 60/413,238
; PRIOR FILING DATE: 2002-09-24
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 87
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-670-911A-1

Query Match 100.0%; Score 480; DB 16; Length 87;
Best Local Similarity 100.0%; Pred. No. 1.1e-48;
Matches 87; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 60

Qy         61 KDMWDKLRKESKNLNIQGSLFELCGSG 87
              |||||||||||||||||||||||||||
Db         61 KDMWDKLRKESKNLNIQGSLFELCGSG 87
```

RESULT 2
US-09-933-767-1202

Sequence 1202, Application US/09933767
Publication No. US20030181692A1
GENERAL INFORMATION:
APPLICANT: Ni et al.
TITLE OF INVENTION: 207 Human Secreted Proteins
FILE REFERENCE: PZ007P2
CURRENT APPLICATION NUMBER: US/09/933,767
CURRENT FILING DATE: 2001-08-22
PRIOR APPLICATION NUMBER: PCT/US01/05614
PRIOR FILING DATE: 2001-02-21
PRIOR APPLICATION NUMBER: 60/184,836
PRIOR FILING DATE: 2000-02-24
PRIOR APPLICATION NUMBER: 60/193,170
PRIOR FILING DATE: 2000-03-29
PRIOR APPLICATION NUMBER: 09/205,258
PRIOR FILING DATE: 1998-12-04
PRIOR APPLICATION NUMBER: PCT/US98/11422
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/048,885
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/049,375
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,881
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,880
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,896
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/049,020
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,876
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,895
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,884
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,894
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,971
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,964
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,882
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,899
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,893
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,900
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,901
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,892
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,915
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/049,019
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,970
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,972
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,916
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/049,373
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,875
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/049,374
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,917
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,949
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,974
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,883
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,897
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,898
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,962
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,963
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,877
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/048,878
PRIOR FILING DATE: 1997-06-06
PRIOR APPLICATION NUMBER: 60/068,054
PRIOR FILING DATE: 1997-12-18
PRIOR APPLICATION NUMBER: 60/068,064
PRIOR FILING DATE: 1997-12-18
PRIOR APPLICATION NUMBER: 60/068,053
PRIOR FILING DATE: 1997-12-18
PRIOR APPLICATION NUMBER: 60/070,923
PRIOR FILING DATE: 1997-12-18
PRIOR APPLICATION NUMBER: 60/073,160
PRIOR FILING DATE: 1998-01-30
PRIOR APPLICATION NUMBER: 60/073,159
PRIOR FILING DATE: 1998-01-30
PRIOR APPLICATION NUMBER: 60/073,165
PRIOR FILING DATE: 1998-01-30
PRIOR APPLICATION NUMBER: 60/073,164
PRIOR FILING DATE: 1998-01-30
PRIOR APPLICATION NUMBER: 60/085,925
PRIOR FILING DATE: 1998-05-18
PRIOR APPLICATION NUMBER: 60/085,921
PRIOR FILING DATE: 1998-05-18
PRIOR APPLICATION NUMBER: 60/085,923
PRIOR FILING DATE: 1998-05-18
PRIOR APPLICATION NUMBER: 60/085,922
PRIOR FILING DATE: 1998-05-18
PRIOR APPLICATION NUMBER: 60/092,921
PRIOR FILING DATE: 1998-07-15
PRIOR APPLICATION NUMBER: 60/094,657
PRIOR FILING DATE: 1998-07-30
NUMBER OF SEQ ID NOS: 1245
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 1202
LENGTH: 143
TYPE: PRT
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: SITE
LOCATION: (49)
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
NAME/KEY: SITE
LOCATION: (50)
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
NAME/KEY: SITE
LOCATION: (51)
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
NAME/KEY: SITE
LOCATION: (52)
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
NAME/KEY: SITE
LOCATION: (53)
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-933-767-1202

Query Match 88.9%; Score 426.5; DB 10; Length 143;
Best Local Similarity 90.9%; Pred. No. 4e-42;
Matches 80; Conservative 0; Mismatches 7; Indels 1; Gaps 1;

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: December 20, 2004, 15:13:37 ; Search time 16 Seconds
(without alignments)
523.179 Million cell updates/sec

Title: US-10-670-911A-1
Perfect score: 480
Sequence: 1 AGKCDAVFKGFSDCLLKLGD.....RKESKNLNIQGSLFELCGSG 87

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR_79:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	480	100.0	142	2	JC6305	neuritin precursor
2	76.5	15.9	2241	2	T20971	hypothetical prote
3	76.5	15.9	2261	2	T20978	hypothetical prote
4	71.5	14.9	195	2	H88996	protein C17B7.4 [i
5	71.5	14.9	2269	2	T28677	rhoptry protein -
6	71	14.8	199	2	T28981	hypothetical prote
7	71	14.8	340	2	B84019	hypothetical prote
8	70	14.6	609	2	E81500	conserved hypothet
9	70	14.6	609	2	H72038	ct651 hypothetical
10	70	14.6	609	2	E86584	CT651 hypothetical
11	69	14.4	290	2	AH1681	5'-3' exonuclease
12	69	14.4	305	2	JC5844	chitinase (EC 3.2.
13	68	14.2	644	1	W1WL58	E1 protein - human
14	67	14.0	442	2	T01731	hypothetical prote
15	66	13.8	429	2	E84952	threonine synthase
16	66	13.8	675	2	F85071	hypothetical prote
17	65.5	13.6	201	2	F88990	protein C36C5.14 [
18	65	13.5	184	2	C88104	protein W10G11.1 [
19	65	13.5	322	2	T20423	hypothetical prote
20	65	13.5	433	2	T25946	hypothetical prote
21	65	13.5	483	2	T19720	hypothetical prote
22	64.5	13.4	231	2	D96925	probable membrane
23	64.5	13.4	751	2	H90410	iron-sulfur protei
24	64	13.3	256	2	G96692	hypothetical prote
25	64	13.3	1016	2	T49686	related to PEP5 pr
26	63.5	13.2	788	2	T25061	hypothetical prote
27	63	13.1	1792	2	T08878	supervillin P205 -
28	63	13.1	2718	2	A23475	G surface protein
29	62.5	13.0	211	2	T01194	hypothetical prote
30	62.5	13.0	1127	2	T30334	AND-1 protein - Af
31	62.5	13.0	1883	2	G82875	hypothetical prote
32	62.5	13.0	2098	2	T18397	protein CTRP - mal
33	62	12.9	1179	2	T04584	TMV resistance pro
34	62	12.9	1365	2	T30198	alkaline phosphata
35	61.5	12.8	99	2	S21461	T-cell surface gly
36	61.5	12.8	331	2	F86633	fatty acid/phospho
37	61.5	12.8	372	1	VVVPK1	coat protein VP1 -
38	61.5	12.8	612	2	H86323	protein F14D16.17
39	61.5	12.8	701	2	S48452	probable membrane
40	61.5	12.8	1276	2	S75801	probable phytochro
41	61	12.7	430	2	D64151	hypothetical prote
42	61	12.7	467	2	A81590	chromosomal replic
43	61	12.7	533	1	S75536	NADH2 dehydrogenas
44	61	12.7	1132	2	H82887	hypothetical prote
45	60.5	12.6	250	2	T29866	hypothetical prote

ALIGNMENTS

RESULT 1
JC6305
neuritin precursor - rat
C;Species: Rattus norvegicus (Norway rat)
C;Date: 21-May-1998 #sequence_revision 29-May-1998 #text_change 09-Jul-2004
C;Accession: JC6305
R;Naeve, G.S.; Ramakrishnan, M.; Kramer, R.; Hevroni, D.; Citri, Y.; Theill, L.E.
Proc. Natl. Acad. Sci. U.S.A. 94, 2648-2653, 1997
A;Title: Neuritin: A gene induced by neural activity and neurotrophins that promotes ne
A;Reference number: JC6305; MUID:97226008; PMID:9122250
A;Accession: JC6305
A;Molecule type: mRNA
A;Residues: 1-142 <NAE>
A;Cross-references: UNIPROT:O08957; GB:U88950
C;Comment: This protein promotes neurite outgrowth and arborization in primary embtyoni
C;Superfamily: rat neuritin
C;Keywords: blocked carboxyl end; disulfide bond; glycoprotein; lipoprotein; phosphatid
F;1-27/Domain: signal sequence #status predicted <SIG>
F;28-115/Product: neuritin #status predicted <MAT>
F;116-142/Domain: carboxyl-terminal propeptide #status predicted <CTP>
F;115/Modified site: GPI-anchor ethanolamine amidated carboxyl end (Asn) (in mature for

Query Match 100.0%; Score 480; DB 2; Length 142;
Best Local Similarity 100.0%; Pred. No. 6.6e-46;
Matches 87; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         28 AGKCDAVFKGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSCTVTALTDCQEGA 87

Qy         61 KDMWDKLRKESKNLNIQGSLFELCGSG 87
              |||||||||||||||||||||||||||
Db         88 KDMWDKLRKESKNLNIQGSLFELCGSG 114
```

RESULT 2
T20971
hypothetical protein F15D3.1 - Caenorhabditis elegans
C;Species: Caenorhabditis elegans
C;Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 15-Oct-1999
C;Accession: T20971
R;White, S.
submitted to the EMBL Data Library, October 1996
A;Reference number: Z19353
A;Accession: T20971
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: DNA
A;Residues: 1-2241 <WIL>
A;Cross-references: EMBL:Z81063; PIDN:CAB02951.1; GSPDB:GN00019; CESP:F15D3.1
A;Experimental source: clone F15D3
C;Genetics:
A;Gene: CESP:F15D3.1

A;Map position: 1
A;Introns: 24/1; 130/3; 172/2; 194/2; 206/1; 235/3; 297/3; 438/2; 497/3; 601/2; 737/3; 8
96/3; 2019/3; 2044/3

Query Match 15.9%; Score 76.5; DB 2; Length 2241;
Best Local Similarity 31.0%; Pred. No. 7.3;
Matches 22; Conservative 10; Mismatches 26; Indels 13; Gaps 2;

Qy 9 KGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSC-----TVTALTDCQEGAKDM 63
Db 1309 KGFEEKLEKVITTLSNVEMGLDDTTGI--------DGSECGGALMEVRALVRMLDGAQEK 1360

Qy 64 WDKLRKESKNL 74
Db 1361 WKDLAENREQL 1371

RESULT 3
T20978
hypothetical protein F15D3.9 - Caenorhabditis elegans
C;Species: Caenorhabditis elegans
C;Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 15-Oct-1999
C;Accession: T20978
R;White, S.
submitted to the EMBL Data Library, October 1996
A;Reference number: Z19353
A;Accession: T20978
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: DNA
A;Residues: 1-2261 <WIL>
A;Cross-references: EMBL:Z81063; PIDN:CAB02958.1; GSPDB:GN00019; CESP:F15D3.9
A;Experimental source: clone F15D3
C;Genetics:
A;Gene: CESP:F15D3.9
A;Map position: 1
A;Introns: 24/1; 130/3; 172/2; 211/1; 240/3; 302/3; 443/2; 502/3; 606/2; 742/3; 828/2; 9
064/3

Query Match 15.9%; Score 76.5; DB 2; Length 2261;
Best Local Similarity 31.0%; Pred. No. 7.3;
Matches 22; Conservative 10; Mismatches 26; Indels 13; Gaps 2;

Qy 9 KGFSDCLLKLGDSMANYPQGLDDKTNIKTVCTYWEDFHSC-----TVTALTDCQEGAKDM 63
Db 1289 KGFEEKLEKVITTLSNVEMGLDDTTGI--------DGSECGGALMEVRALVRMLDGAQEK 1340

Qy 64 WDKLRKESKNL 74
Db 1341 WKDLAENREQL 1351

RESULT 4
H88996
protein C17B7.4 [imported] - Caenorhabditis elegans
C;Species: Caenorhabditis elegans
C;Date: 10-May-2001 #sequence_revision 10-May-2001 #text_change 09-Jul-2004
C;Accession: H88996
R;anonymous, The C. elegans Sequencing Consortium.
Science 282, 2012-2018, 1998
A;Title: Genome sequence of the nematode C. elegans: a platform for investigating biolog
A;Reference number: A75000; MUID:99069613; PMID:9851916
A;Note: see websites genome.wustl.edu/gsc/C_elegans/ and www_sanger.ac.uk/Projects/C_ele
A;Note: published errata appeared in Science 283, 35, 1999; Science 283, 2103, 1999; and
A;Accession: H88996
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-195 <STO>
A;Cross-references: UNIPROT:O45156; GB:chr_V; PIDN:AAC04398.1; PID:g2911826; GSPDB:GN000
C;Genetics:
A;Gene: C17B7.4
A;Map position: 5
C;Superfamily: Caenorhabditis elegans hypothetical protein C01B7.7

Query Match 14.9%; Score 71.5; DB 2; Length 195;
Best Local Similarity 31.0%; Pred. No. 1.8;
Matches 27; Conservative 10; Mismatches 37; Indels 13; Gaps 5;

Qy 5 DAVFKGFSDCLLKLGDSMANYPQGLDDKT-----NIKTVCTYWEDFHSCTVTALTDCQEG 59
Db 37 ELTPKKFFVCLYRFGDFMTKM-YFLDVKSPNSMNKFKTSCLSMAD---CTES--FECQNN 90

Qy 60 AK--DMWDKLRKESKNLNIQGSLFELC 84
Db 91 KEPTDSSKKVRESCETLNFLGTDFITC 117

RESULT 5
T28677
rhoptry protein - Plasmodium yoelii
C;Species: Plasmodium yoelii
C;Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 09-Jul-2004
C;Accession: T28677; C45521
R;Keen, J.; Sinha, K.; Brown, K.; Holder, A.
Mol. Biochem. Parasitol. 65, 171-177, 1994
A;Title: A gene coding for a high molecular mass rhoptry protein of Plasmodium yoelii
A;Reference number: Z20508; MUID:95021522; PMID:7935623
A;Accession: T28677
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: DNA
A;Residues: 1-2269 <KEE>
A;Cross-references: UNIPROT:Q26223; EMBL:L27838; NID:g457145; PID:g457146; PIDN:AAA2
R;Keen, J.; Holder, A.; Playfair, J.; Lockyer, M.; Lewis, A.
Mol. Biochem. Parasitol. 42, 241-246, 1990
A;Title: Identification of the gene for a Plasmodium yoelii rhoptry protein. Multiple
A;Reference number: A45521; MUID:91101660; PMID:2270106
A;Accession: C45521
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 2131-2269 <KE2>
A;Cross-references: GB:M34283

Query Match 14.9%; Score 71.5; DB 2; Length 2269;
Best Local Similarity 22.8%; Pred. No. 26;
Matches 23; Conservative 21; Mismatches 32; Indels 25; Gaps 3;

Qy 8 FKGFSDCLLKLGDS----------MANYPQGLDDKTNIKTVCTYWEDFHSCTV 50
Db 15 FKGLNESMIKLKNSGILRKYTISNQIKNKLNVSTYPEGREGFTSSLELAKSWEKTKLETI 74

Qy 51 TALTDCQEGA-------KDMWDK-LRKESKNLNIQGSLFEL 83
Db 75 TELTKSNEETVRLEKEIRELFKKYLDEEAERKYLEGLKLEL 115

RESULT 6
T28981
hypothetical protein T28A11.16 - Caenorhabditis elegans
C;Species: Caenorhabditis elegans
C;Date: 29-Oct-1999 #sequence_revision 29-Oct-1999 #text_change 09-Jul-2004
C;Accession: T28981
R;Rohlfing, T.
submitted to the EMBL Data Library, January 1997
A;Description: The sequence of C. elegans cosmid T28A11.
A;Reference number: Z20550
A;Accession: T28981
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: DNA
A;Residues: 1-199 <ROH>
A;Cross-references: UNIPROT:P91512; EMBL:U80027; PIDN:AAC48125.1; GSPDB:GN00023; CESP:T
A;Experimental source: strain Bristol N2; clone T28A11
C;Genetics:
A;Gene: CESP:T28A11.16
A;Map position: 5
A;Introns: 53/3; 183/3
C;Superfamily: Caenorhabditis elegans hypothetical protein C01B7.7